Close Menu

NEW YORK (GenomeWeb) – Veracyte announced after the close of the market on Monday that its fourth quarter revenues grew 32 percent year over year and beat the consensus Wall Street estimate.

For the three months ended Dec. 31, 2018, the South San Francisco, California-based genomics diagnostics firm posed $25.8 million in revenues, up from $19.6 million in Q4 2017 and above analysts' average estimate of $24.4 million.

Total genomic test volume was up 28 percent year over year to 9,154 tests in the quarter, Veracyte said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.

Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.

The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.

In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.